Last reviewed · How we verify

Russian Academy of Medical Sciences — Portfolio Competitive Intelligence Brief

Russian Academy of Medical Sciences pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mucofalk Mucofalk marketed Other
Resveratrol Pill Resveratrol Pill marketed Natural polyphenol / Sirtuin activator SIRT1, antioxidant pathways, NF-κB Cardiovascular, Metabolic health, Anti-aging
cyclosporine or tacrolimus cyclosporine or tacrolimus marketed Calcineurin inhibitor Calcineurin (protein phosphatase 2B) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Albert Einstein Healthcare Network · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Andrew B Adams · 1 shared drug class
  4. Armando Torres Ramírez · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Astellas Pharma China, Inc. · 1 shared drug class
  7. Astellas Pharma Europe Ltd. · 1 shared drug class
  8. Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Russian Academy of Medical Sciences:

Cite this brief

Drug Landscape (2026). Russian Academy of Medical Sciences — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/russian-academy-of-medical-sciences. Accessed 2026-05-18.

Related